Vitamin D Inhibits Monocyte/Macrophage Proinflammatory Cytokine Production by Targeting MAPK Phosphatase-1

Yong Zhang, Donald Y. M. Leung, Brittany N. Richers, Yusen Liu, Linda K. Remigio, David W. Riches and Elena Goleva

*J Immunol* published online 1 February 2012
http://www.jimmunol.org/content/early/2012/02/01/jimmunol.1102412

**Subscription** Information about subscribing to *The Journal of Immunology* is online at: http://jimmunol.org/subscription

**Permissions** Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Vitamin D Inhibits Monocyte/Macrophage Proinflammatory Cytokine Production by Targeting MAPK Phosphatase-1

Yong Zhang,* Donald Y. M. Leung,*† Brittany N. Richers,* Yusen Liu,‡§ Linda K. Remigio,*, David W. Riches,* and Elena Goleva*

It is estimated that 1 billion people around the world are vitamin D deficient. Vitamin D deficiency has been linked to various inflammatory diseases. However, the mechanism by which vitamin D reduces inflammation remains poorly understood. In this study, we investigated the inhibitory effects of physiologic levels of vitamin D on LPS-stimulated inflammatory response in human blood monocytes and explored potential mechanisms of vitamin D action. We observed that two forms of the vitamin D, 1,25(OH)2D3, and 25(OH)D3, dose dependently inhibited LPS-induced p38 phosphorylation at physiologic concentrations, IL-6 and TNF-α production by human monocytes. Upon vitamin D treatment, the expression of MAPK phosphatase-1 (MKP-1) was significantly upregulated in human monocytes and murine bone marrow-derived macrophages (BMM). Increased binding of the vitamin D receptor and increased histone H4 acetylation at the identified vitamin D response element of the murine and human MKP-1 promoters were demonstrated. Moreover, in BMM from MKP1−/− mice, the inhibition of LPS-stimulated p38 phosphorylation by vitamin D was completely abolished. Vitamin D inhibition of LPS-induced IL-6 and TNF-α production by BMM from MKP1−/− mice was significantly reduced as compared with wild-type mice. In conclusion, this study identified the upregulation of MKP-1 by vitamin D as a novel pathway by which vitamin D inhibits LPS-induced p38 activation and cytokine production in monocytes/macrophages.

Vitamin D is well known for its role in calcium homeostasis and maintenance of bone metabolism (1). However, recent evidence suggests that vitamin D plays important roles in both innate and adaptive immunity (2). Vitamin D levels are routinely tested by assessing the concentration of the major circulating form of the vitamin D, 25(OH)D3, in serum; this form of vitamin D has a half life of 15 d, whereas the active form of vitamin D, 1,25(OH)2D3, has a short half life of ~15 h (3–5).

1,25(OH)2D3 acts as a ligand for the vitamin D receptor (VDR). VDR forms a heterodimer with a retinoid X receptor and regulates gene expression by binding to the vitamin D response element (VDRE). VDRE had been shown to be predominantly located in introns and intergenic intervals (7). VDRE is characterized by direct repeats of two hexameric core-binding motifs (preferentially being AGTTCA). The binding of VDR to VDRE recruits coactivators and enzymes with histone acetylation activity, causing the structural changes in chromatin, therefore, facilitating gene transcription (10).

LPS, a component of the Gram-negative bacterial cell wall, induces cytokine production by monocytes/macrophages. LPS has been implicated in sepsis caused by Gram-negative bacteria and induces intense inflammatory and procoagulant responses, which can be lethal (11). LPS is recognized by cell surface TLR4, which initiates intracellular signal transduction cascades (12). The MAPKs activated by LPS [ERK, JNK, and p38 (12)] are critical regulators of proinflammatory cytokine production, including TNF-α and IL-6 (13, 14). Although these proinflammatory cytokines enhance host defense, excessive production leads to unresolved inflammation (15). Therefore, feedback control of MAPK activation is necessary. MAPK phosphatases (MKP) inactivate MAPKs by dephosphorylating conserved threonine and tyrosine residues of the activated MAPK (16). MKP-1 is known to preferentially inactivate p38 and JNK, leading to subsequent inhibition of proinflammatory cytokines production (17, 18). In the current study, we examined mechanisms of the vitamin D-mediated suppression of LPS-activated monocytes/macrophages. We found that vitamin D inhibits LPS-induced cytokine production by upregulating MKP-1, thereby attenuating p38 activation.

Materials and Methods

Materials

1,25(OH)2D3, 25(OH)D3, and monoclonal anti-β-actin Ab were purchased from Sigma-Aldrich (St. Louis, MO). HyQTase was purchased from HyClone Laboratories (Logan, UT). TrypLE Express was purchased from In VitroGen (Carlsbad, CA). Phosphorylated (p)-p38 and p38 Abs were purchased from Cell Signaling Technology (Danvers, MA). Anti-mouse and anti-rabbit HRP-labeled IgG were purchased from Amersham Biosciences (Piscataway, NJ). Rabbit polyclonal Ab to VDR, rabbit polyclonal Ab to MKP-1, Radioimmunoprecipitation Assay Lysis Buffer, and Protein A/G PLUS-agarose beads were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal Ab to histone H4 and acetylated histone H4 as well as the Magna Chromatin Immunoprecipitation (ChIP) A/G ChIP Kit were purchased from Millipore (Temecula, CA). Chemilu-
minescent reagents were purchased from Perkin-Elmer Life Sciences (Waltham, MA). All the reagents and conjugated Abs against p-p38, p-ERK1/2, p-JNK, and IL-6 in flow cytometry analysis were purchased from BD Biosciences (San Diego, CA), whereas the TLR4 Ab was purchased from eBioscience (San Diego, CA).

Study subjects
Blood samples were collected from normal healthy adults. Approval was received from the National Jewish Health Institutional Review Board (Denver, CO) for the study.

Mice
C57BL/6 × 129 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). MKP-1−/− mice were provided by Bristol-Myers Squibb (19). Six- to 8-wk-old males were used in the experiments. All experiments using these animals were approved by the Institutional Animal Care and Use Committee at National Jewish Health. This institution has an animal welfare assurance number (A3026-1) on file with the Office of Protection and Research Risks.

Cell culture and treatment
PBMC were isolated from heparinized, venous blood of healthy donors by Ficoll-Hypaque density gradient centrifugation as described elsewhere. PBMC were cultured in hormone-free medium (phenol-red free RPMI 1640 medium containing 5% charcoal-stripped FCS, 50 μg/ml streptomycin, and 50 U/ml penicillin) with a range of doses of 1,25(OH)2D3 or 25(OH)D3 for 24 h, followed by stimulation with 10 ng/ml LPS for 10 min. Cells were then fixed with 2% formaldehyde at 37˚C for 10 min. Adherent cells were collected by using HyQTAse and TrypLE consecutively and combined with suspension cells. Cells were permeabilized in 500 μl 1× perm/wash buffer I (BD Pharmingen) at 4˚C for 30 min, incubated in 100 μl 1× perm/wash buffer I containing FITC-conjugated anti–CD14 and allopregnanolone-conjugated anti–p-p38 Abs at 4˚C for 1 h, and washed with 1× perm/wash buffer I. The samples were then analyzed by flow cytometry (BD FACSCalibur Flow Cytometer; BD Biosciences, Franklin Lakes, NJ) and CellQuest Pro software. The flow data were displayed as a percentage of CD14+ cells that express p-p38 (the gate for p-p38+ cells was set on the basis of isotype control binding).

To examine the effects of vitamin D on p38 activation by LPS, PBMC were preincubated in hormone-free medium containing 1.25(OH)2D3 or 25(OH)D3 for 24 h, followed by stimulation with 10 ng/ml LPS for 10 min. Cells were then fixed with 2% formaldehyde at 37˚C for 10 min. Adherent cells were collected by using HyQTAse and TrypLE consecutively and combined with suspension cells. Cells were permeabilized in 500 μl 1× perm/wash buffer I (BD Pharmingen) at 4˚C for 30 min, incubated in 100 μl 1× perm/wash buffer I containing FITC-conjugated anti–CD14 and allopregnanolone-conjugated anti–p-p38 Abs at 4˚C for 1 h, and washed with 1× perm/wash buffer I. The samples were then analyzed by flow cytometry (BD FACSCalibur Flow Cytometer; BD Biosciences, Franklin Lakes, NJ) and CellQuest Pro software. The flow data were displayed as a percentage of CD14+ cells that express p-p38 (the gate for p-p38+ cells was set on the basis of isotype control binding).

Flow cytometry analysis
To analyze the effects of vitamin D on p38 activation by LPS, PBMC were preincubated in hormone-free medium containing 1.25(OH)2D3 or 25(OH)D3 for 24 h, followed by stimulation with 10 ng/ml LPS for 10 min. Cells were then fixed with 2% formaldehyde at 37˚C for 10 min. Adherent cells were collected by using HyQTAse and TrypLE consecutively and combined with suspension cells. Cells were permeabilized in 500 μl 1× perm/wash buffer I (BD Pharmingen) at 4˚C for 30 min, incubated in 100 μl 1× perm/wash buffer I containing FITC-conjugated anti–CD14 and allopregnanolone-conjugated anti–p-p38 Abs at 4˚C for 1 h, and washed with 1× perm/wash buffer I. The samples were then analyzed by flow cytometry (BD FACSCalibur Flow Cytometer; BD Biosciences, Franklin Lakes, NJ) and CellQuest Pro software. The flow data were displayed as a percentage of CD14+ cells that express p-p38 (the gate for p-p38+ cells was set on the basis of isotype control binding).

Statistical analyses
Results were expressed as the mean ± SEM. Statistical analysis was conducted using GraphPad Prism, version 5 (GraphPad Software, La Jolla, CA). The data were analyzed by the paired Student t test, pairing by experiment. Before testing, paired difference distributions were examined for outliers, which can indicate violation to the normality assumption of the t test. No outliers were apparent. Tests were performed between specific treatments and LPS treatments or between vitamin D treatment and control. Unpaired t test was used for comparison of responses between cells from wild-type and MKP-1−/− mice. Differences were considered significant at p < 0.05. A minimum of three independent experiments was conducted to allow for statistical comparisons.

RESULTS
Pretreatment of human PBMC with vitamin D inhibits LPS-induced p38 phosphorylation in human monocytes
In this study, we examined the role of vitamin D in the regulation of LPS responses. Human PBMC were pretreated with vitamin D for 24 h, followed by stimulation with 10 ng/ml LPS. Both forms of the vitamin D, an active form, 1,25(OH)2D3, and 25(OH)D3, were tested. Monocytes/macrophages have previously been shown to be able to locally convert 25(OH)D3 into an active form (23). Vitamin D levels are normally measured by serum 25(OH)D3 levels, because this form of vitamin D is more stable, whereas the active form of vitamin D has a short half life (5). In these experiments, we assessed the anti-inflammatory effects of 25(OH)D3 doses that are related to vitamin D deficiency (15 ng/ml) and vitamin D
sufficiency (30 ng/ml, lower normal range; 50 and 70 ng/ml, upper normal range for the serum vitamin D levels) (1, 23, 24).

The binding of LPS to TLR4 on monocytes triggers immediate activation of MAPK, which together with activation of the canonical IKK pathway regulate NF-κB activation to induce pro-inflammatory cytokine production (25). We investigated whether the pretreatment of cells with vitamin D affects the activation of MAPK. The phosphorylation of three subfamilies of MAPK—ERK, JNK, and p38—was examined by flow cytometry. Human PBMC were pretreated with vitamin D for 24 h, followed by 10 min of treatment with 10 ng/ml LPS. After short-term stimulation with LPS, phosphorylation of p38 MAPK in CD14+ cells was induced. Monocytes cultured in media for 24 h had high level of p-JNK, which was not changed after LPS stimulation for 10 min. No ERK phosphorylation was observed 10 min after LPS treatment in these cells. As expected, LPS treatment did not activate CD3+ T cells.

As shown by flow cytometry (Fig. 1A), 6.5 ± 1.2% CD14+ cells expressed p-p38 MAPK (p-p38) prior to LPS treatment, and 23.6 ± 2.5% CD14+ cells expressed p-p38 after 10 min of LPS treatment (n = 4, p < 0.05). After LPS stimulation, a significant increase in the percentage of CD14+ cells that express p-p38 was observed; there was no change in p-p38 mean fluorescence intensity (Fig. 1C). It was found that 15 ng/ml 25(OH)D3, a concentration corresponding to the insufficient serum vitamin D levels in humans (24), did not suppress LPS-induced p38 phosphorylation in human monocytes. PBMC were cultured in hormone-free medium containing 25(OH)D3 (A) or 1,25(OH)2D3 (B) for 24 h, followed by stimulation with 10 ng/ml LPS for 10 min. (A and B) As shown by flow cytometry, vitamin D pretreatment inhibits LPS-induced p38 phosphorylation in CD14+ cells (n = 4). (C) Representative flow cytometry data on the effects of LPS and vitamin D/LPS on p38 activation in human monocytes is shown. (D) Pretreatment with vitamin D significantly inhibits p-p38 expression by the cells as shown by Western blot. Whole-cell extracts from LPS or vitamin D/LPS-treated adherent PBMC fraction were prepared and blotted against p-p38 and total p38. (E) Fold changes in the densitometry of p-p38 normalized to total p38 MAPK expression are provided. Values represent mean ± SEM (n = 4 experiments).
tion (Fig. 1A), whereas significant inhibition of LPS-induced p38 phosphorylation was achieved with ≥30 ng/ml 25(OH)D$_3$ (Fig. 1A). Maximum inhibition was achieved with 50 ng/ml 25(OH)D$_3$ (a mean inhibition of 78% [$n = 4$; $p < 0.01$]). Similarly, a dose-dependent inhibition of LPS-induced p38 activation was observed in human monocytes when the cells were pretreated with active vitamin D (Fig. 1B, 1C). The maximum inhibitory effect was achieved when the cells were preincubated with 0.4 ng/ml (1 nM) 1,25(OH)$_2$D$_3$ (mean inhibition of 70% [$n = 4$; $p < 0.01$]). Inhibition of LPS-induced p38 phosphorylation by vitamin D was confirmed by Western blot analysis, because 10 nM 1,25(OH)$_2$D$_3$ significantly suppressed LPS-induced p38 phosphorylation by 75% in adherent fraction of the PBMC ($n = 4$; $p < 0.01$) (Fig. 1D, 1E). As confirmed by flow cytometry, this adherent fraction of PBMC consisted of 85–90% CD14$^+$ monocytes. Both flow cytometry and Western blot evaluations demonstrated that in vitamin D-pretreated cells, LPS-induced p-38 phosphorylation was inhibited to the level of p-p38 phosphorylation observed in cells cultured with media alone.

**Pretreatment with vitamin D inhibits LPS-induced IL-6 and TNF-α production by human monocytes**

Upon LPS stimulation, monocytes produce proinflammatory cytokines, such as TNF-α and IL-6 (26). Persistent inflammatory

![FIGURE 2. Vitamin D inhibits LPS-induced cytokine production in human monocytes. PBMC were cultured in hormone-free medium containing 25 (OH)D$_3$ (A, C) or 1,25(OH)$_2$D$_3$ (B, D, E) for 24 h, followed by 24 h of treatment with 10 ng/ml LPS. IL-6 (A, B) and TNF-α (C, D) mRNA levels in the total PBMC were detected by real-time PCR after 24 h of stimulation with LPS ($n = 4$). IL-6 protein levels (E) in the culture supernatants following LPS stimulation were detected by ELISA ($n = 4$). (F) IL-6 expression in CD14$^+$ cells was detected in human monocytes by flow cytometry after 24 h of pretreatment with 10 nM 1,25(OH)$_2$D$_3$, followed by 6 h of stimulation with LPS. The percentage of CD14$^+$ cells expressing IL-6 was calculated. Values represent mean ± SEM ($n = 4$ experiments). (G) Representative flow cytometry data on the effects of LPS and vitamin D/LPS on IL-6 production by human monocytes are shown.**
responses can damage host tissues (27, 28). To examine whether changes in LPS-induced p38 activation in the presence of vitamin D influenced cytokine production, human PBMC were preincubated as above with either 1,25(OH)₂D₃ or 25(OH)D₃ for 24 h, followed by stimulation with 10 ng/ml LPS for 24 h. LPS treatment significantly induced IL-6 mRNA production by the cells \((p < 0.05)\). When the cells were preincubated with \(\geq 30 ng/ml\) 25(OH)D₃, a significant inhibition of LPS-induced IL-6 mRNA expression was observed \((p < 0.01)\) (Fig. 2A). No inhibition of LPS-induced IL-6 expression was observed when the cells were cultured with 15 ng/ml 25(OH)D₃ (Fig. 2A). All doses of the active form of vitamin D significantly inhibited LPS-induced IL-6 mRNA expression (Fig. 2B). The degree of suppression of IL-6 mRNA by 30 ng/ml (70 nM) 25(OH)D₃ was comparable to the inhibition achieved with 0.04 ng/ml (0.1 nM) of the active form of vitamin D (Fig. 2A, 2B). Similar vitamin D effects were observed in LPS-induced TNF-α mRNA expression (Fig. 2C, 2D).

Upon stimulation with LPS, the amounts of IL-6 protein in culture supernatants increased from a basal level of 330 ± 96 to 1385 ± 277 pg/ml \((p < 0.05)\). When the cells were pretreated with 10 nM 1,25(OH)₂D₃ for 24 h, LPS-induced IL-6 production by the cells was significantly inhibited by a mean of 77% \((n = 4\); \(p < 0.01)\) (Fig. 2E). The inhibition of IL-6 production was more efficient with 10 nM 1,25(OH)₂D₃ as compared with 1 nM 1,25(OH)₂D₃ \((p < 0.05)\) (Fig. 2E). These data were confirmed by flow cytometry as the amount of IL-6–producing monocytes was significantly increased after the stimulation with LPS from basal 0.8 ± 0.4 to 29.7 ± 4.9% \((n = 4\); \(p < 0.01)\) (Fig. 2F, 2G). However, when the cells were pretreated with 10 nM 1,25(OH)₂D₃ for 24 h, the amount of IL-6–producing CD14⁺ cells induced by LPS was significantly inhibited by a mean of 67% \((n = 4\); \(p < 0.05)\) (Fig. 2F, 2G).

**Vitamin D pretreatment induces MKP-1 expression**

MKP-1 plays a critical role in switching off p38 signaling and cytokine production in monocytes/macrophages after the inflammatory stimuli (18). Because vitamin D pretreatment significantly inhibited LPS-induced p38 phosphorylation, we examined whether this process was mediated via MKP-1 or other phosphatases. Pretreatment of human PBMC with 10 nM 1,25(OH)₂D₃ for 24 h resulted in significant increases in MKP-1 mRNA (2.5 ± 0.1-fold; \(p < 0.05)\) (Fig. 3A) and protein (3.1 ± 0.4-fold; \(p < 0.05)\) (Fig. 3C, 3D) expressions by the adherent PBMC fraction, which consisted mainly of monocytes. The expression of MKP-5, another phosphatase that has been reported to dephosphorylate p38, was not changed in adherent PBMC fraction after 24 h of culture with 1,25(OH)₂D₃ (Fig. 3B).

To examine the mechanism of MKP-1 upregulation by vitamin D, we used murine BMM cultures. Similarly to human monocytes, when murine BMM from wild-type mice (C57BL/6 × 129) were preincubated with 10 nM 1,25(OH)₂D₃, a significant increase in MKP-1 mRNA expression was observed. The maximum increase in MKP-1 mRNA expression was found after 6 h of treatment with vitamin D (2.6 ± 0.2-fold increase, \(n = 3\); \(p < 0.01)\) (Fig. 3E).

We examined the presence of potential VDRE sites in the human and murine MKP-1 promoter. A VDRE (labeled E4.7) sequence AGTTCATAATCATATCA was located at -4708 to -4694 from the transcriptional start site of human MKP-1 gene. A VDRE (labeled E33) sequence AGTTCAATGGCCCTTCA was located at -33410 to -33396 from the transcriptional start site of murine MKP-1 gene. Underlined nucleotides directly interact with VDR. Several additional half VDRE sites were also found at the murine MKP-1 promoter, with the closest one with a sequence AGTTCA (labeled E0.9) located at -930 to -925 from the transcriptional start...

**FIGURE 3.** Vitamin D induces MKP-1 by human and mouse monocytes/macrophages. Human PBMC were cultured in hormone-free medium containing 10 nM 1,25(OH)₂D₃ or vehicle control for 24 h. An adherent PBMC fraction was collected. (A and B) Human MKP-1 and MKP-5 mRNA levels were tested by real-time PCR and normalized to β-actin mRNA levels \((n = 6 \text{ experiments})\). (C) Human MKP-1 protein levels were tested by Western blot. (D) Fold changes in the densitometry of human MKP-1 to β-actin expression from Western blot are provided \((n = 4 \text{ experiments})\). (E) Murine BMM cells were cultured in DMEM for 18 h and then treated with 10 nM 1,25(OH)₂D₃ or vehicle control for 6 h. mRNA levels of murine MKP-1 were tested and normalized to β-actin mRNA \((n = 3 \text{ experiments})\). All values represent mean ± SEM.
site (the scheme of the potential VDR binding sites in the human and murine MKP-1 promoter is shown in Fig. 4A). VDR binding and histone H4 acetylation at the E4.7, E33, and E0.9 sites of the human and murine MKP-1 promoters were tested by ChIP assays. We found that treatment of adherent PBMC with 10 nM 1,25(OH)2D3 for 24 h enhanced VDR binding and histone H4 acetylation by 2.4 ± 0.5-fold ($p < 0.05$) and 3.0 ± 0.8-fold ($p < 0.05$), respectively, at the E4.7 site of the human MKP-1 promoter (Fig. 4B, 4C). We found that treatment of murine BMM with 10 nM 1,25(OH)2D3 for 6 h enhanced VDR binding and histone H4 acetylation by 3.7 ± 0.4-fold ($p < 0.05$) and 6.26 ± 0.04-fold ($p < 0.05$), respectively, at the E33 site of the murine MKP-1 promoter (Fig. 4D, 4E). No increase in VDR binding and only a slight yet significant ($p < 0.01$) increase in histone H4 acetylation were observed at the E0.9 site (Fig. 4D, 4E). These data suggest that vitamin D-bound VDR interacts with the VDRE upstream of MKP-1 gene, thus, potentially influencing MKP-1 transcription.

**Vitamin D inhibits p38 phosphorylation in macrophages derived from the bone marrow of the wild-type but not the MKP-1 $^{−/−}$ mice**

Next, we tested the ability of vitamin D to inhibit LPS-induced p38 phosphorylation in macrophages derived from the bone marrow of the wild-type and MKP-1 $^{−/−}$ mice (29). Ten minutes of treatment with LPS resulted in a significant increase in p38 phosphorylation by 4.8 ± 0.2-fold ($n = 3$; $p < 0.05$) and 8.2 ± 0.2-fold ($n = 3$; $p < 0.01$) in wild-type and MKP-1 $^{−/−}$ macrophages, respectively (Fig. 5A, 5B). As shown by Western blot analysis, pretreatment with 10 nM 1,25(OH)2D3 significantly inhibited LPS-induced p38 MAPK activation by a mean of 93% ($n = 3$; $p < 0.05$) in BMM from wild-type mice (Fig. 5B), but this inhibition was abolished in BMM from MKP1 $^{−/−}$ mice (Fig. 5B).

**Inhibition of LPS-induced production of IL-6 and TNF-α in bone marrow macrophages from wild-type mice by vitamin D was significantly compromised in MKP-1 $^{−/−}$ mice**

To examine whether inhibition of LPS-induced p38 activation by vitamin D in mouse macrophages influenced cytokine production, macrophages derived from the bone marrow of wild-type and MKP-1 $^{−/−}$ mice were preincubated with either 10 nM 1,25(OH)2D3 or 75 nM (30 ng/ml) 25(OH)D3 for 24 h, followed by stimulation with 10 ng/ml LPS for 24 h. Significantly higher levels of IL-6 and TNF-α were observed in culture supernatants of the LPS-treated BMM from MKP-1 $^{−/−}$ mice as compared with wild-type mice ($p < 0.01$ and $p < 0.05$, respectively). The amounts of LPS-induced IL-6 protein in culture supernatants were inhibited 67 and 61% by 1,25(OH)2D3 and 25(OH)D3, respectively, in wild-type macrophages. LPS-induced IL-6 production was inhibited only to 18 and 33%, respectively, in MKP-1 $^{−/−}$ macrophages. LPS-induced TNF-α protein in culture supernatants by 48 and 57%, respectively, in wild-type macrophages, whereas the inhibition of LPS-induced production of these cytokines was only 16 and 29%, respectively, in MKP-1 $^{−/−}$ macrophages (Fig. 6B).

**Discussion**

In this study, we examined the effects of vitamin D at physiologic concentrations on LPS-stimulated inflammatory responses in monocytes/macrophages. We found that both 1,25(OH)2D3, an active form of vitamin D, and 25(OH)D3, which requires conversion by monocytes into an active form (23), dose dependently inhibited p38 phosphorylation and cytokines, IL-6 and TNF-α, and production in LPS-stimulated human monocytes. Upon vitamin D treatment, the expression of MKP-1 phosphatase mRNA and protein was significantly upregulated in both human monocytes and murine BMM. We demonstrated that vitamin D treat-

**FIGURE 4.** Vitamin D regulates MKP-1 expression. (A) Schematic representation of the potential VDRE in human and murine MKP-1 promoter. (B and C) The recruitment of VDR to E4.7 of human MKP-1 promoter and histone H4 acetylation at this site as determined by ChIP assay after 24 h of treatment of human adherent PBMC with vitamin D. (D and E) The recruitment of VDR to E33 and E0.9 VDRE sites of the murine MKP-1 promoter and histone H4 acetylation at these sites as determined by ChIP assay after 6 h of treatment of murine BMM with vitamin D. The quantity of anti-VDR Ab-precipitated DNA was normalized to Input DNA, and anti-acetylated histone H4 Ab-precipitated DNA was normalized to anti-histone H4 Ab precipitated DNA. Values represent mean ± SEM ($n = 3$ experiments). TSS, transcriptional start site.
ment increased VDR binding to a putative VDRE in both human and murine MKP-1 promoter and enhanced histone H4 acetylation near this VDRE site. With macrophages derived from MKP-1<sup>−/−</sup> mice, we further demonstrated that vitamin D was no longer able to suppress LPS-induced p38 activation, followed by the compromised ability to inhibit LPS-induced IL-6 and TNF-α production in the absence of MKP-1. Our current study therefore identified the upregulation of MKP-1 by physiologic concentrations of vitamin D as a novel pathway by which vitamin D inhibits LPS-induced p38 activation and cytokine production in monocytes/macrophages.

In recent years, vitamin D deficiency in humans has received significant attention (1, 24). According to the recent brief of the National Center for the Health Statistics in 2001–2006, 32% of the U.S. population had serum 25(OH)D<sub>3</sub> levels < 20 ng/ml; 8% of the U.S. population had serum 25(OH)D<sub>3</sub> levels < 12 ng/ml (30). Aside from its classical role as a modulator of calcium metabolism and bone health, vitamin D has been shown to have potent anti-inflammatory effects and consequently has been considered for adjunctive therapy for numerous chronic diseases including asthma, arthritis, and prostate cancer (4, 31, 32). A variety of pro- and anti-inflammatory effects for the vitamin D had been reported previously (33, 34). It has been shown that vitamin D can directly induce the production of the important antimicrobial peptides, cathelicidin and human β-defensin 4, by human monocytes/macrophages and epithelial cells (23, 35). Antiproliferative and proapoptotic activity has been shown in vitamin D-treated tumor cells because of the induction of cyclin-dependent kinase inhibitors p21<sup>Waf/Cip</sup> and p27<sup>Kip</sup> and inhibition of c-Myc and anti-apoptotic Bcl-2 (32). Vitamin D had been demonstrated to suppress prostaglandin pathways in the tumor cell lines via inhibition of cyclooxygenase-2 production and stimulation of 15-hydroxy-prostaglandin production by the cells (32). Vitamin D has also been shown to interfere with NF-κB activation and signaling by increasing the expression of IκBα in the cells, thus interfering with the nuclear translocation of the activated NF-κB subunits (36). It has also been reported that vitamin D can influence dendritic cells’ maturation and function (37).

The current study found that human monocytes are capable of responding to treatment with two different forms of vitamin D: 1,25(OH)<sub>2</sub>D<sub>3</sub> and 25(OH)D<sub>3</sub>. 25(OH)D<sub>3</sub> is converted into a functionally active form, 1,25(OH)<sub>2</sub>D<sub>3</sub>, by the enzyme 25-hydroxyvitamin D<sub>3</sub>-1α-hydroxylase (CYP27b1), a process that primarily occurs in
VITAMIN D INHIBITS LPS ACTION

Vitamin D, through its receptor (VDR), can regulate a variety of proteins involved in immune responses. In monocytes/macrophages, vitamin D can inhibit LPS-induced cytokine production, suggesting that VDR plays a role in immune modulation. This inhibition is likely due to the VDR binding to specific DNA sequences, called vitamin D response elements (VDREs), which can recruit coactivators or corepressors and alter gene expression. The inhibition of LPS-induced cytokine production by vitamin D is supported by both in vitro and in vivo studies, indicating that vitamin D can regulate immune responses effectively.

References